A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Summary

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

Timeline

Start

2017-12-15

Primary completion

2019-06-21

Completion

2019-06-21

Outcome

Outcome not reported

Stopped (Business): “Study stopped due to business reasons.”

Drugs

Indications